Income statement
USD
Annual
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -43M | -39M | -23M | -28M | -33M |
| EBITDA | -42M | -37M | -21M | -26M | -31M |
| Net Income | -43M | -40M | -24M | -29M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.74
+3.95% today
1Y Change
+25.54%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PolyPid Ltd. (PYPD) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $4.74 and up 25.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +57.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +57.4%, free cash flow +100.0% with operating margin 0.0% and ROIC -95.2%. Stock Foundry combines PYPD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PYPD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PYPD Max Drawdown
-17.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PYPD and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$34.2M
-17.7% YoY
Free Cash Flow
-$28.1M
-27.5% YoY
Revenue Growth
+0.0%
EPS Growth
+57.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -43M | -39M | -23M | -28M | -33M |
| EBITDA | -42M | -37M | -21M | -26M | -31M |
| Net Income | -43M | -40M | -24M | -29M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10M | 9M | 5M | 16M | 6M |
| Total Assets | 44M | 26M | 15M | 25M | 22M |
| Total Liabilities | 8M | 20M | 17M | 18M | 11M |
| Shareholder Equity | — | — | — | — | — |
| Total Debt | 0 | 14M | 12M | 10M | 3M |
| Net Debt | — | — | — | — | — |
Cash flow positioning
2026 Full Year
Operating Cash Flow
28M
-28.0% YoY
Capital Expenditures
—
Free Cash Flow
28M
-27.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-291.4%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.